Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia

 


Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a Phase 2 clinical study investigating the sequential use of azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia

IRB Protocol #

12-1283

Trial Status

OPEN

Principle Investigator

DAN POLLYEA

Sponsor

UCCC

Contact

AARON FULLERTON at -- or --

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : The amount of time you participate in this study will depend on how your disease responds and how you tolerate the treatment. After you stop study treatment, you will be asked to come to the clinic for a final visit. // Eligibility includes but is not limited to patients 18 years of age or older with relapsed and refractory acute myeloid leukemia Eligibility includes but is not limited to patients 18 years of age or older with relapsed and refractory acute myeloid leukemia